臺灣博碩士論文加值系統

鴉片類藥物是臨床處理中重度疼痛，最有效也最被廣泛使用的藥物。然而長期使用鴉片類藥物止痛卻也會伴隨產生藥物的耐受性。脊椎管內鴉片類藥物投與將藥物直接送至中樞神經產生藥效，是非常有效的止痛方式但卻也更容易產生藥物耐受性。傳統神經科學以神經元為中心的思維下，鴉片類藥物耐受性的致病機轉著重於Opioid receptor的internalization、NMDA receptor的upregulation或glutamate transporter 的down regulation。然而這些現象都只能部分解釋耐受性的成因。最近在齧齒類實驗動物上的研究結果顯示神經膠細胞的活化及發炎性物質的過度表現、也就是所謂的神經炎性反應在神經病變疼痛與類鴉片耐受性的致病機轉上有重要的角色。然而相關的人體研究證據則相當稀少。
在本研究的臨床部分，我們首先嘗試建立國內最完整的，有關體外可程控式植入型脊椎內給藥系統的照護流程。包括合適病患的選取、脊椎內嗎啡藥物輸注測試、手術方式的改進、長期追蹤與品質提升計畫。我們紀錄並分析了流程建立初期的病患，其脊椎管內嗎啡的劑量的改變、治療相關併發症的發生率與後續處理及病患日常生活功能的改善程度。藉由給予足夠劑量的脊椎管內嗎啡，病患的疼痛控制與生活品質皆能大幅改善。然而在這當中我們也發現所有接受脊椎內嗎啡輸注療法的病患，其嗎啡的劑量皆快速的增加，遠遠超過病情的演進。
以臨床的照護觀察到的現象為起點，在研究倫理委員會核准後，我們進行了一系列的轉譯醫學研究。我們首先分析了已產生類鴉片藥物耐受性病患的腦脊髓液中發炎相關因子的濃度。包括TNF-alpha、 CXCL1、CXCL10、CCL2、CX3CL1及CXCL12並與未暴露類鴉片藥物的對照組受試者比較。研究結果發現，已經對類鴉片止痛藥產生耐受性的病患群，其腦脊髓液中的CXCL1及CXCL12濃度明顯高於未暴露類鴉片藥物的對照組。進一步我們更發現CXCL1的濃度與病患所接受的類鴉片止痛藥物劑量成高度正相關。
接著我們建立轉譯動物實驗模式，藉由實驗鼠的閃尾反應，評估嗎啡的止痛效果及相關發炎因子對類鴉片耐受性產生的影響。在實驗大鼠投予嗎啡誘發藥物耐受性後，大鼠脊髓組織之CXCL1 及CXCL12 mRNA皆顯著增加。雖然單獨給予椎管內CXCL1或CXCL12並不會改變老鼠的基礎閃尾行為，然而椎管內給予CXCL1或CXCL12卻會大幅降低腹腔內給予嗎啡所造成的急性止痛效果。接著我們參照臨床長期椎管內類鴉片輸注用於頑固疼痛的處置，建立植入皮下微幫浦進行長期椎管內嗎啡輸注並誘發大鼠產生藥物耐受性的實驗模式。我們發現耐受性的發生會因同時給予嗎啡與CXCL1或CXCL12 而加速。反之 若被嗎啡輸注時一併給予CXCL1或CXCL12的中和抗體則會延緩耐受性的發生。針對CXCL1 訊息傳遞給予其受體CXCR2的拮抗劑antileukinate hexapeptide，或針對CXCL12 訊息傳遞給予其受體CXCR4的拮抗劑 AMD3100，則可更有效的延緩嗎啡耐受性的發生。
綜合以上的實驗結果，我們藉由臨床到實驗動物的轉譯醫學研究模式驗證了趨化激素CXCL1與CXCL12可能參與鴉片類止痛藥耐受性的形成。阻斷 CXCL1/CXCR2 與 CXCL12/CXCR4 的訊息傳遞路徑則可以延緩藥物耐受性的產生並降低其嚴重度。因此針對CXCL1/CXCR2 與 CXCL12/CXCR4 的訊息傳遞路徑進行介入將是治療類鴉片止痛藥耐受性的新藥研發之潛力標的。

Opioid analgesics remain the most effective and widely used analgesics for the management of moderate to severe pain. However, the efficacy of long-term opioid analgesics is progressively attenuated by tolerance, preventing adequate pain relief under stable opioid dosages for chronic pain patients. Although intrathecal opioid delivery provides very effective analgesia by acting directly on central nervous system, opioid analgesic tolerance is also accelerated. Classical neuron-centered concepts such as internalization of opioid receptors, up-regulation of N-methyl-D-aspartate receptor function, or down-regulation of glutamate transporter activity can only partially explain the phenomenon of tolerance. Recent evidence showing glial activation and upregulated inflammatory mediators in the rodent central nervous system has confirmed the pivotal role of neuroinflammation in neuropathic pain or opioid tolerance, or both. However, human evidence is still sparse.
In clinical part of this study, we developed comprehensive management protocol for totally implantable programmable intrathecal drug delivery system from patient selection, intraspinal morphine trial, surgical procedure to follow up program. Intrathecal morphine dosage adjustment, treatment related complications and patient functional outcomes are recorded regularly and analyzed. By delivering liberal dose of intrathecal morphine, pain severity decreased significantly. Due to much better pain control and improved quality of life, functional performance status also improved. Intrathecal morphine delivery by using totally implantable programmable device is an effective alternative method to relieve refractory cancer pain.
Based on our clinical practice, we further conducted subsequent translational research by investigating the intraspinal cytokine and chemokine profiles of opioid-tolerant cancer patients after research ethic committee approval. Cerebrospinal fluid (CSF) samples from opioid-tolerant cancer patients and opioid-naive subjects were compared. The CSF levels of tumor necrosis factor-alpha, CXCL1, CXCL10, CCL2, CX3CL1 and CXCL12 were assayed. CXCL1 and CXCL12 levels in CSF were significantly upregulated in the opioid-tolerant group. Further analysis revealed that CXCL1 level was strongly positively correlated with opioid dosage.
The rat tail flick test was utilized to assess the effects of intrathecal CXCL1 or CXCL12 on morphine-induced acute antinociception and analgesic tolerance. After induction of tolerance by intrathecal morphine infusion, the spinal cord CXCL1 and CXCL12 messenger RNA were significantly upregulated. Although CXCL1 or CXCL12 infusion alone did not affect baseline tail flick latency, the analgesic tolerance was accelerated by intrathecal infusion of CXCL1 or CXCL12 in daily intraperitoneal morphine injection of paradigm. After establishing tolerance by intrathecal continuous infusion of morphine, its development was accelerated by co-administration of CXCL1 or CXCL12. On the contrary, tolerance was attenuated by co-administration of CXCL1 or CXCL12 neutralizing antibody or corresponding receptor antagonists.
CXCL1 and CXCL12 were upregulated in both opioid-tolerant patients and rodents. The onset and extent of opioid tolerance was affected by antagonizing intrathecal CXCL1/CXCR2 and CXCL12/CXCR4 signaling. Therefore, the CXCL1/CXCR2 and CXCL12/CXCR4 signal pathways may be novel drug targets for the treatment of opioid tolerance.

縮寫 p1
中文摘要 p4
英文摘要 p7
第一章 緒論 (Introduction)
1.1 The Role of Opioid Therapy in Pain Management p11
1.2 Pharmacology of Opioids and Mechanism of Opioid Tolerance p13
1.3 Neuroinflammation Counteracts Opioid Analgesia p20
1.4 The Biological Function of Chemokines CXCL1 and CXCL12 p25
第二章 研究材料與方法 (Materials and Methods)
2-1 IDDS Clinical Study p35
2-2 Translational Human Study p39
2-3 Translational Rat Study p42
2-4 Statistical Analysis p49
第三章 Development and Validation of Intraspinal Opioid Delivery System Services for Refractory Cancer Pain Management p52
第四章 Role of Spinal CXCL1 (GROα) in Opioid Tolerance: A Human-to-Rodent Translational Study p63
第五章 CXCL12/CXCR4 Signaling Contributes to the Pathogenesis of Opioid Tolerance: A Translational Study p83
第六章 結論與展望 (Conclusion and Prospect) p100
Publication p105
Reference p109

Abbadie, C., S. Bhangoo, Y. De Koninck, M. Malcangio, S. Melik-Parsadaniantz and F. A. White (2009). "Chemokines and pain mechanisms." Brain Res Rev 60(1): 125-134.

Al-Hasani, R. and M. R. Bruchas (2011). "Molecular mechanisms of opioid receptor-dependent signaling and behavior." Anesthesiology 115(6): 1363-1381.

Alexander, G. M., M. A. van Rijn, J. J. van Hilten, M. J. Perreault and R. J. Schwartzman (2005). "Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS." Pain 116(3): 213-219.

Belverud, S., A. Mogilner and M. Schulder (2008). "Intrathecal pumps." Neurotherapeutics 5(1): 114-122.

Bhangoo, S. K., M. S. Ripsch, D. J. Buchanan, R. J. Miller and F. A. White (2009). "Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy." Mol Pain 5: 48.

Bhatia, M. and A. Hegde (2007). "Treatment with antileukinate, a CXCR2 chemokine receptor antagonist, protects mice against acute pancreatitis and associated lung injury." Regul Pept 138(1): 40-48.

Bodnar, R. J. (2016). "Endogenous opiates and behavior: 2014." Peptides 75: 18-70.

Burton, A. W., A. Rajagopal, H. N. Shah, T. Mendoza, C. Cleeland, S. J. Hassenbusch, 3rd and J. F. Arens (2004). "Epidural and intrathecal analgesia is effective in treating refractory cancer pain." Pain Med 5(3): 239-247.

Caraceni, A., G. Hanks, S. Kaasa, M. I. Bennett, C. Brunelli, N. Cherny, O. Dale, F. De Conno, M. Fallon, M. Hanna, D. F. Haugen, G. Juhl, S. King, P. Klepstad, E. A. Laugsand, M. Maltoni, S. Mercadante, M. Nabal, A. Pigni, L. Radbruch, C. Reid, P. Sjogren, P. C. Stone, D. Tassinari and G. Zeppetella (2012). "Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC." The Lancet Oncology 13(2): e58-e68.

Chapman, C. R., D. L. Lipschitz, M. S. Angst, R. Chou, R. C. Denisco, G. W. Donaldson, P. G. Fine, K. M. Foley, R. M. Gallagher, A. M. Gilson, J. D. Haddox, S. D. Horn, C. E. Inturrisi, S. S. Jick, A. G. Lipman, J. D. Loeser, M. Noble, L. Porter, M. C. Rowbotham, K. M. Schoelles, D. C. Turk, E. Volinn, M. R. Von Korff, L. R. Webster and C. M. Weisner (2010). "Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base." J Pain 11(9): 807-829.

Chen, X., E. B. Geller, T. J. Rogers and M. W. Adler (2007). "Rapid heterologous desensitization of antinociceptive activity between mu or delta opioid receptors and chemokine receptors in rats." Drug Alcohol Depend 88(1): 36-41.

Cheng, I. C., C. S. Chang and W. I. Tsay (2015). "Long-term usage of narcotic analgesics by chronic intractable noncancer pain patients in Taiwan from 2003 to 2012." J Formos Med Assoc.: In Press

Chia, Y. Y., K. Liu, J. J. Wang, M. C. Kuo and S. T. Ho (1999). "Intraoperative high dose fentanyl induces postoperative fentanyl tolerance." Can J Anaesth 46(9): 872-877.

Cui, Y., X. X. Liao, W. Liu, R. X. Guo, Z. Z. Wu, C. M. Zhao, P. X. Chen and J. Q. Feng (2008). "A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia." Brain Behav Immun 22(1): 114-123.

Dhawan, P. and A. Richmond (2002). "Role of CXCL1 in tumorigenesis of melanoma." J Leukoc Biol 72(1): 9-18.

Dubovy, P., I. Klusakova, I. Svizenska and V. Brazda (2010). "Spatio-temporal changes of SDF1 and its CXCR4 receptor in the dorsal root ganglia following unilateral sciatic nerve injury as a model of neuropathic pain." Histochem Cell Biol 133(3): 323-337.

Eck, M., B. Schmausser, K. Scheller, S. Brandlein and H. K. Muller-Hermelink (2003). "Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma." Clin Exp Immunol 134(3): 508-515.

Farina, C., F. Aloisi and E. Meinl (2007). "Astrocytes are active players in cerebral innate immunity." Trends Immunol 28(3): 138-145.

Fischer, L., A. Korfel, S. Pfeiffer, P. Kiewe, H. D. Volk, H. Cakiroglu, T. Widmann and E. Thiel (2009). "CXCL13 and CXCL12 in central nervous system lymphoma patients." Clin Cancer Res 15(19): 5968-5973.

Fluckiger, B., H. Knecht, S. Grossmann and P. Felleiter (2008). "Device-related complications of long-term intrathecal drug therapy via implanted pumps." Spinal Cord 46(9): 639-643.

Franciotta, D., E. Zardini, S. Ravaglia, G. Piccolo, L. Andreoni, R. Bergamaschi, A. Romani, E. Tavazzi, P. Naldi, M. Ceroni and E. Marchioni (2006). "Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis." J Neurol Sci 247(2): 202-207.

Gao, Y. J., L. Zhang, O. A. Samad, M. R. Suter, K. Yasuhiko, Z. Z. Xu, J. Y. Park, A. L. Lind, Q. Ma and R. R. Ji (2009). "JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain." J Neurosci 29(13): 4096-4108.

Grace, P. M., M. R. Hutchinson, S. F. Maier and L. R. Watkins (2014). "Pathological pain and the neuroimmune interface." Nat Rev Immunol 14(4): 217-231.

Griffith, J. W., C. L. Sokol and A. D. Luster (2014). "Chemokines and chemokine receptors: positioning cells for host defense and immunity." Annu Rev Immunol 32: 659-702.

Groves, M. D., K. R. Hess, V. K. Puduvalli, H. Colman, C. A. Conrad, M. R. Gilbert, J. Weinberg, M. Cristofanilli, W. K. Yung and T. J. Liu (2009). "Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma." J Neurooncol 94(2): 229-234.

Guo, W., H. Wang, M. Watanabe, K. Shimizu, S. Zou, S. C. LaGraize, F. Wei, R. Dubner and K. Ren (2007). "Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain." J Neurosci 27(22): 6006-6018.

Guyon, A. (2014). "CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems." Front Cell Neurosci 8: 65.

Hameed, H., M. Hameed and P. J. Christo (2010). "The effect of morphine on glial cells as a potential therapeutic target for pharmacological development of analgesic drugs." Curr Pain Headache Rep 14(2): 96-104.

Hammond, M. E., V. Shyamala, M. A. Siani, C. A. Gallegos, P. H. Feucht, J. Abbott, G. R. Lapointe, M. Moghadam, H. Khoja, J. Zakel and P. Tekamp-Olson (1996). "Receptor recognition and specificity of interleukin-8 is determined by residues that cluster near a surface-accessible hydrophobic pocket." J Biol Chem 271(14): 8228-8235.

Haskill, S., A. Peace, J. Morris, S. A. Sporn, A. Anisowicz, S. W. Lee, T. Smith, G. Martin, P. Ralph and R. Sager (1990). "Identification of three related human GRO genes encoding cytokine functions." Proc Natl Acad Sci U S A 87(19): 7732-7736.

Hassenbusch, S., K. Burchiel, R. J. Coffey, M. J. Cousins, T. Deer, M. B. Hahn, S. D. Pen, K. A. Follett, E. Krames, J. N. Rogers, O. Sagher, P. S. Staats, M. Wallace and K. D. Willis (2002). "Management of intrathecal catheter-tip inflammatory masses: a consensus statement." Pain Med 3(4): 313-323.

Heinisch, S., J. Palma and L. G. Kirby (2011). "Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey." Brain Behav Immun 25(2): 360-372.

Horvath, R. J. and J. A. DeLeo (2009). "Morphine enhances microglial migration through modulation of P2X4 receptor signaling." J Neurosci 29(4): 998-1005.
Hu, X. M., Y. N. Liu, H. L. Zhang, S. B. Cao, T. Zhang, L. P. Chen and W. Shen (2015). "CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats." J Neurochem 132(4): 452-463.

Hutchinson, M. R., B. D. Coats, S. S. Lewis, Y. Zhang, D. B. Sprunger, N. Rezvani, E. M. Baker, B. M. Jekich, J. L. Wieseler, A. A. Somogyi, D. Martin, S. Poole, C. M. Judd, S. F. Maier and L. R. Watkins (2008). "Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia." Brain Behav Immun 22(8): 1178-1189.

Hutchinson, M. R., S. S. Lewis, B. D. Coats, D. A. Skyba, N. Y. Crysdale, D. L. Berkelhammer, A. Brzeski, A. Northcutt, C. M. Vietz, C. M. Judd, S. F. Maier, L. R. Watkins and K. W. Johnson (2009). "Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)." Brain Behav Immun 23(2): 240-250.

Ji, R. R., Z. Z. Xu and Y. J. Gao (2014). "Emerging targets in neuroinflammation-driven chronic pain." Nat Rev Drug Discov 13(7): 533-548.

Johnson, E. A., T. L. Dao, M. A. Guignet, C. E. Geddes, A. I. Koemeter-Cox and R. K. Kan (2011). "Increased expression of the chemokines CXCL1 and MIP-1alpha by resident brain cells precedes neutrophil infiltration in the brain following prolonged soman-induced status epilepticus in rats." J Neuroinflammation 8: 41.

Johnston, I. N., E. D. Milligan, J. Wieseler-Frank, M. G. Frank, V. Zapata, J. Campisi, S. Langer, D. Martin, P. Green, M. Fleshner, L. Leinwand, S. F. Maier and L. R. Watkins (2004). "A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine." J Neurosci 24(33): 7353-7365.

Kang, J., M. H. Jiang, H. J. Min, E. K. Jo, S. Lee, M. Karin, T. Y. Yune and S. J. Lee (2011). "IKK-beta-mediated myeloid cell activation exacerbates inflammation and inhibits recovery after spinal cord injury." Eur J Immunol 41(5): 1266-1277.

Kissin, I., P. T. Brown, C. A. Robinson and E. L. Bradley, Jr. (1991). "Acute tolerance in morphine analgesia: continuous infusion and single injection in rats." Anesthesiology 74(1): 166-171.

Lee, Y. H., S. H. Kim, Y. Kim, Y. Lim, K. Ha and S. Y. Shin (2012). "Inhibitory effect of the antidepressant imipramine on NF-kappaB-dependent CXCL1 expression in TNFalpha-exposed astrocytes." Int Immunopharmacol 12(4): 547-555.

Lilius, T. O., P. V. Rauhala, O. Kambur and E. A. Kalso (2009). "Modulation of morphine-induced antinociception in acute and chronic opioid treatment by ibudilast." Anesthesiology 111(6): 1356-1364.

Lin, C. P., C. H. Hsu, W. M. Fu, H. M. Chen, Y. H. Lee, M. S. Lai and Y. Y. Shao (2016). "Key opioid prescription concerns in cancer patients: A nationwide study." Acta Anaesthesiol Taiwan, In Press

Lin, C. P., K. H. Kang, T. H. Lin, M. Y. Wu, H. C. Liou, W. J. Chuang, W. Z. Sun and W. M. Fu (2015). "Role of spinal CXCL1 (GROalpha) in opioid tolerance: a human-to-rodent translational study." Anesthesiology 122(3): 666-676.

Lin, T. C., C. H. Hsu, C. C. Lu, Y. C. Tsai and S. T. Ho (2010). "Chronic opioid therapy in patients with chronic noncancer pain in Taiwan." J Anesth 24(6): 882-887.

Lomas-Neira, J. L., C. S. Chung, P. S. Grutkoski, E. J. Miller and A. Ayala (2004). "CXCR2 inhibition suppresses hemorrhage-induced priming for acute lung injury in mice." J Leukoc Biol 76(1): 58-64.

Luo, X., W. L. Tai, L. Sun, Q. Qiu, Z. Xia, S. K. Chung and C. W. Cheung (2014). "Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice." PLoS One 9(8): e104860.

Mao, J., B. Sung, R. R. Ji and G. Lim (2002). "Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity." J Neurosci 22(18): 8312-8323.

Melik Parsadaniantz, S., C. Rivat, W. Rostene and A. Reaux-Le Goazigo (2015). "Opioid and chemokine receptor crosstalk: a promising target for pain therapy?" Nat Rev Neurosci 16(2): 69-78.

Menichella, D. M., B. Abdelhak, D. Ren, A. Shum, C. Frietag and R. J. Miller (2014). "CXCR4 chemokine receptor signaling mediates pain in diabetic neuropathy." Mol Pain 10: 42.

Milligan, E. D., E. M. Sloane and L. R. Watkins (2008). "Glia in pathological pain: a role for fractalkine." J Neuroimmunol 198(1-2): 113-120.

Milligan, E. D. and L. R. Watkins (2009). "Pathological and protective roles of glia in chronic pain." Nat Rev Neurosci 10(1): 23-36.

Myers, J., V. Chan, V. Jarvis and C. Walker-Dilks (2010). "Intraspinal techniques for pain management in cancer patients: a systematic review." Support Care Cancer 18(2): 137-149.

Myers, R. R., W. M. Campana and V. I. Shubayev (2006). "The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets." Drug Discov Today 11(1-2): 8-20.

Narita, M., H. Mizoguchi, M. Narita, H. Nagase, T. Suzuki and L. F. Tseng (2001). "Involvement of spinal protein kinase Cgamma in the attenuation of opioid mu-receptor-mediated G-protein activation after chronic intrathecal administration of [D-Ala2,N-MePhe4,Gly-Ol(5)]enkephalin." J Neurosci 21(11): 3715-3720.

National Comprehensive Cancer Network. (2015). "NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain Version 1.2015." from http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf.

Obata, H., J. C. Eisenach, H. Hussain, T. Bynum and M. Vincler (2006). "Spinal glial activation contributes to postoperative mechanical hypersensitivity in the rat." J Pain 7(11): 816-822.

Ohtori, S., M. Suzuki, T. Koshi, M. Takaso, M. Yamashita, G. Inoue, K. Yamauchi, S. Orita, Y. Eguchi, K. Kuniyoshi, N. Ochiai, S. Kishida, J. Nakamura, Y. Aoki, T. Ishikawa, G. Arai, M. Miyagi, H. Kamoda, M. Suzuki, T. Toyone and K. Takahashi (2011). "Proinflammatory cytokines in the cerebrospinal fluid of patients with lumbar radiculopathy." Eur Spine J 20(6): 942-946.

Okie, S. (2010). "A flood of opioids, a rising tide of deaths." N Engl J Med 363(21): 1981-1985.

Pizzo, P. A. and N. M. Clark (2012). "Alleviating suffering 101--pain relief in the United States." N Engl J Med 366(3): 197-199.

Portenoy, R. K. (2011). "Treatment of cancer pain." Lancet 377(9784): 2236-2247.

Pranzatelli, M. R., E. D. Tate, N. R. McGee and J. A. Colliver (2013). "Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders." J Neurol Sci 326(1-2): 53-58.

Quinten, C., C. Coens, M. Mauer, S. Comte, M. A. Sprangers, C. Cleeland, D. Osoba, K. Bjordal, A. Bottomley and E. C. Groups (2009). "Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials." Lancet Oncol 10(9): 865-871.

Raghavendra, V., M. D. Rutkowski and J. A. DeLeo (2002). "The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats." J Neurosci 22(22): 9980-9989.

Raghavendra, V., F. Y. Tanga and J. A. DeLeo (2004). "Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats." Neuropsychopharmacology 29(2): 327-334.

Ramesh, G., A. G. MacLean and M. T. Philipp (2013). "Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain." Mediators Inflamm 2013: 480739.

Reaux-Le Goazigo, A., C. Rivat, P. Kitabgi, M. Pohl and S. Melik Parsadaniantz (2012). "Cellular and subcellular localization of CXCL12 and CXCR4 in rat nociceptive structures: physiological relevance." Eur J Neurosci 36(5): 2619-2631.

Reaux-Le Goazigo, A., J. Van Steenwinckel, W. Rostene and S. Melik Parsadaniantz (2013). "Current status of chemokines in the adult CNS." Prog Neurobiol 104: 67-92.

Richmond, A., D. H. Lawson, D. W. Nixon and R. K. Chawla (1985). "Characterization of autostimulatory and transforming growth factors from human melanoma cells." Cancer Res 45(12 Pt 1): 6390-6394.

Ripamonti, C. I., D. Santini, E. Maranzano, M. Berti, F. Roila and E. G. W. Group (2012). "Management of cancer pain: ESMO Clinical Practice Guidelines." Ann Oncol 23 Suppl 7: vii139-154.

Rivat, C., S. Sebaihi, J. Van Steenwinckel, S. Fouquet, P. Kitabgi, M. Pohl, S. Melik Parsadaniantz and A. Reaux-Le Goazigo (2014). "Src family kinases involved in CXCL12-induced loss of acute morphine analgesia." Brain Behav Immun 38: 38-52.

Shavit, Y., G. Wolf, I. Goshen, D. Livshits and R. Yirmiya (2005). "Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance." Pain 115(1-2): 50-59.

Shen, C. H., R. Y. Tsai and C. S. Wong (2012). "Role of neuroinflammation in morphine tolerance: effect of tumor necrosis factor-alpha." Acta Anaesthesiol Taiwan 50(4): 178-182.

Shen, W., X. M. Hu, Y. N. Liu, Y. Han, L. P. Chen, C. C. Wang and C. Song (2014). "CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord." J Neuroinflammation 11: 75.

Shimoyama, N., M. Shimoyama, A. M. Davis, D. T. Monaghan and C. E. Inturrisi (2005). "An antisense oligonucleotide to the N-methyl-D-aspartate (NMDA) subunit NMDAR1 attenuates NMDA-induced nociception, hyperalgesia, and morphine tolerance." J Pharmacol Exp Ther 312(2): 834-840.

Song, P. and Z. Q. Zhao (2001). "The involvement of glial cells in the development of morphine tolerance." Neurosci Res 39(3): 281-286.

Stearns, L., R. Boortz-Marx, S. Du Pen, G. Friehs, M. Gordon, M. Halyard, L. Herbst and J. Kiser (2005). "Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices." J Support Oncol 3(6): 399-408.

Stein, C., H. Reinecke and H. Sorgatz (2010). "Opioid use in chronic noncancer pain: guidelines revisited." Curr Opin Anaesthesiol 23(5): 598-601.

Sun, J., S. Liu, M. Mata, D. J. Fink and S. Hao (2012). "Transgene-mediated expression of tumor necrosis factor soluble receptor attenuates morphine tolerance in rats." Gene Ther 19(1): 101-108.

Szabo, I., X. H. Chen, L. Xin, M. W. Adler, O. M. Howard, J. J. Oppenheim and T. J. Rogers (2002). "Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain." Proc Natl Acad Sci U S A 99(16): 10276-10281.

Tai, Y. H., Y. H. Wang, J. J. Wang, P. L. Tao, C. S. Tung and C. S. Wong (2006). "Amitriptyline suppresses neuroinflammation and up-regulates glutamate transporters in morphine-tolerant rats." Pain 124(1-2): 77-86.

Temel, J. S., J. A. Greer, A. Muzikansky, E. R. Gallagher, S. Admane, V. A. Jackson, C. M. Dahlin, C. D. Blinderman, J. Jacobsen, W. F. Pirl, J. A. Billings and T. J. Lynch (2010). "Early palliative care for patients with metastatic non-small-cell lung cancer." N Engl J Med 363(8): 733-742.

Timothy, D., S. K. Elliot, J. H. Samuel, B. Allen, C. David, D. Stuart, E. James, E. Michael, G. Eric, K. Phillip, L. Robert, M. Gladstone, M. Nagy, P. Sunil, P. Joshua, R. Richard, S. Michael, S. Todd, S. Peter, S.-H. Michael, S. Lisa, K. D. Willis, W. William, F. Kenneth, H. Marc, L. Leong, R. James, W. Mark, B. Eric, C. Michael and D. Anne Ver (2007). "Polyanalgesic Consensus Conference 2007: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel." Neuromodulation 10(4): 300-328.

Verbeke, H., K. Geboes, J. Van Damme and S. Struyf (2012). "The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer." Biochim Biophys Acta 1825(1): 117-129.

Verbeke, H., S. Struyf, G. Laureys and J. Van Damme (2011). "The expression and role of CXC chemokines in colorectal cancer." Cytokine Growth Factor Rev 22(5-6): 345-358.

Wang, B., D. T. Hendricks, F. Wamunyokoli and M. I. Parker (2006). "A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer." Cancer Res 66(6): 3071-3077.

Wang, J. G., J. A. Strong, W. Xie, R. H. Yang, D. E. Coyle, D. M. Wick, E. D. Dorsey and J. M. Zhang (2008). "The chemokine CXCL1/growth related oncogene increases sodium currents and neuronal excitability in small diameter sensory neurons." Mol Pain 4: 38.

Watkins, L. R., M. R. Hutchinson, K. C. Rice and S. F. Maier (2009). "The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia." Trends Pharmacol Sci 30(11): 581-591.

Wen, Y. R., P. H. Tan, J. K. Cheng, Y. C. Liu and R. R. Ji (2011). "Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance." J Formos Med Assoc 110(8): 487-494.

White, F. A., S. K. Bhangoo and R. J. Miller (2005). "Chemokines: integrators of pain and inflammation." Nat Rev Drug Discov 4(10): 834-844.

White, F. A., H. Jung and R. J. Miller (2007). "Chemokines and the pathophysiology of neuropathic pain." Proc Natl Acad Sci U S A 104(51): 20151-20158.

White, F. A., J. Sun, S. M. Waters, C. Ma, D. Ren, M. Ripsch, J. Steflik, D. N. Cortright, R. H. Lamotte and R. J. Miller (2005). "Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion." Proc Natl Acad Sci U S A 102(39): 14092-14097.

Williams, J. T., S. L. Ingram, G. Henderson, C. Chavkin, M. von Zastrow, S. Schulz, T. Koch, C. J. Evans and M. J. Christie (2013). "Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance." Pharmacol Rev 65(1): 223-254.

Wilson, N. M., H. Jung, M. S. Ripsch, R. J. Miller and F. A. White (2011). "CXCR4 signaling mediates morphine-induced tactile hyperalgesia." Brain Behav Immun 25(3): 565-573.

Wu, C. L. and S. N. Raja (2011). "Treatment of acute postoperative pain." Lancet 377(9784): 2215-2225.

Yang, R. H., J. A. Strong and J. M. Zhang (2009). "NF-kappaB mediated enhancement of potassium currents by the chemokine CXCL1/growth related oncogene in small diameter rat sensory neurons." Mol Pain 5: 26.

Zech, D. F., S. Grond, J. Lynch, D. Hertel and K. A. Lehmann (1995). "Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study." Pain 63(1): 65-76.

Zhang, Z. J., D. L. Cao, X. Zhang, R. R. Ji and Y. J. Gao (2013). "Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons." Pain 154(10): 2185-2197.

Zhao, C. M., R. X. Guo, F. Hu, J. L. Meng, L. Q. Mo, P. X. Chen, X. X. Liao, Y. Cui and J. Q. Feng (2012). "Spinal MCP-1 contributes to the development of morphine antinociceptive tolerance in rats." Am J Med Sci 344(6): 473-479.

Zuo, Z. (2005). "The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance." Anesth Analg 101(3): 728-734, table of contents.
Zwijnenburg, P. J., H. M. de Bie, J. J. Roord, T. van der Poll and A. M. van Furth (2003). "Chemotactic activity of CXCL5 in cerebrospinal fluid of children with bacterial meningitis." J Neuroimmunol 145(1-2): 148-153.